Why Nortriptyline Still Matters
The tricyclics are supposed to be dead. SSRIs buried them thirty years ago: safer in overdose, cleaner side-effect profiles, no blood levels to chase, no ECG to remember. For most patients, most of the time, that verdict is correct and you should reach for a first-line agent. But "rarely first-line" is not the same as "never useful," and a clinician who has retired the entire tricyclic class has given up several things that nothing else in the formulary does as well.
Of the tricyclics, nortriptyline is the one to learn. It is a secondary amine, the active metabolite of amitriptyline, and everything good about it follows from that one fact. Secondary amines shed most of the receptor promiscuity that makes tertiary tricyclics miserable. Nortriptyline is among the least anticholinergic TCAs, it is the least likely to drop blood pressure and cause falls, and it is one of only three tricyclics with a serum level you can act on. Amitriptyline is a blunderbuss; nortriptyline is closer to a scalpel.
Its niches are real and underserved: melancholic depression (where TCAs outperform SSRIs), depression with chronic neuropathic pain (where a single drug treats both, with an NNT around 3 for the pain), treatment-resistant depression, and relapse prevention after ECT, where nortriptyline plus lithium is the gold-standard combination. It earns its place when your melancholic, anhedonic, guilt-ridden, early-waking patient has failed two SSRIs, when your depressed patient also has diabetic neuropathy, or when your patient has just finished a course of ECT and you are terrified of the 80% six-month relapse rate.
Nortriptyline is safe and effective when you respect three things: the U-shaped therapeutic window (50–150 ng/mL), the heart, and the overdose risk. In practice that means four habits. Get a level, get an ECG in the patients who need one, don't hand a lethal quantity to an acutely suicidal patient, and titrate slowly. With those in place you have a precise, well-tolerated, level-guided antidepressant that treats populations the SSRIs leave behind.
How to Use Nortriptyline With Confidence
Be honest about why the tricyclics fell out of favor. They never stopped working; they carry a set of hesitations that make a busy prescriber reach past them: They're lethal in overdose. They need an ECG. They need blood levels. They're bad for the heart. They give old people dry mouth and falls. Each of those concerns has a kernel of truth, and each is manageable with a system. Here is the system.
The Core Reframe
Nortriptyline feels intimidating for the same reason lithium does: it demands attention. It has a narrow-ish therapeutic index, a real (if favorable-for-a-TCA) cardiac profile, and a monitoring requirement. That requirement is also the best thing about it. Unlike almost every other antidepressant, nortriptyline tells you whether it's in the patient's blood at an effective concentration, so you are not guessing. The serum level confirms adherence, catches the ultra-rapid and ultra-slow metabolizers, and lets you titrate to a target instead of to a hunch.
A supposedly "treatment-resistant" patient on 100 mg who feels nothing may be a rapid metabolizer sitting at 30 ng/mL, subtherapeutic despite an ordinary dose. Another patient on 75 mg may be toxic at 250 ng/mL. You cannot tell these two apart clinically. A single blood level sorts them out, and that is the entire case for nortriptyline over drugs you have to dose blind.
Addressing the Specific Fears
True, and this is the fear that calls for real judgment. Tricyclics kill through their type 1A antiarrhythmic (sodium-channel-blocking) effect on cardiac conduction; the class carries the highest overdose morbidity and mortality of any antidepressant group. You manage it through the supply, not by avoiding the drug: keep a lethal quantity out of the hands of an acutely suicidal patient. Dispense in small quantities (a week or two at a time), enlist family to hold the supply, and reassess risk at every visit. For the melancholic, chronically ill, or post-ECT patient who is not acutely suicidal, this is entirely workable. Match the drug to the patient's current risk state, not to their diagnosis alone.
Only in the patients who need one, and it's a five-minute test. Get a baseline ECG in anyone over ~40, or with any cardiac history or risk factor, before starting. You're looking for a baseline QTc and any conduction delay (a wide QRS, a bundle branch block, a long PR). A young, healthy patient with a normal heart does not need an ECG to start nortriptyline.
They're the reason to pick this drug. You draw one level, 8 to 12 hours after the dose, at least 5 to 6 days after reaching a steady dose, and you aim for 50–150 ng/mL. That's it, and you now know more about this patient's pharmacology than you know about almost any SSRI patient you've ever treated. Build it into your workflow the way you'd build in a lithium level.
Nortriptyline modestly raises heart rate (~11%) and reduces heart-rate variability (~14%), and in patients with active ischemic heart disease the adverse-cardiac-event rate ran ~18% vs ~2% for an SSRI. So avoid it within 6 months of an MI and in unstable cardiac disease, and screen with an ECG. In a patient with a structurally normal heart, though, therapeutic nortriptyline is well tolerated. The cardiac caution is a reason to screen, not to abstain.
They can't take amitriptyline, the most anticholinergic, most orthostatic tricyclic. Nortriptyline is the secondary amine you choose for older and fall-prone patients, because it's among the least anticholinergic and the least orthostatic of the class. Start low, go slow and check orthostatic vitals, and it becomes a reasonable option when a TCA is clearly indicated (melancholic depression, neuropathic pain).
The Partnership
As with lithium, the level is something you and the patient manage together. Tell the patient up front: "This medicine has a target blood level, and getting the dose right depends on a blood test drawn at the right time. I need you to get your blood drawn in the morning, about 8 to 12 hours after your evening dose, before you take that day's pill, and to be honest with me about whether you're taking it, because the level tells me." Patients who understand that the level confirms adherence tend to be adherent; patients who understand the overdose risk tend to respect the pill count. You don't carry the monitoring alone, and that shared work is what makes the drug safe.
Being monitorable is what makes nortriptyline precise. The blood level turns a tricyclic you would otherwise dose in the dark into the one antidepressant where you can look at a number and know exactly where you stand.
Part 1: Indications
FDA-Approved Use
- Major depressive disorder (the primary, on-label indication)
The Evidence-Based Clinical Uses
Melancholic depression: the classic tricyclic advantage. When depression takes the melancholic form (pervasive anhedonia, ruminating guilt, appetite and weight loss, early-morning awakening, prominent psychomotor change), tricyclics outperform SSRIs. Lump all depressions together and TCAs and modern antidepressants come out roughly equal; the tricyclic edge appears in the melancholic and severe subtypes. If your patient has textbook melancholia and hasn't done well on serotonergic drugs, nortriptyline is a rational, evidence-supported move.
Depression with chronic neuropathic pain. Tricyclics relieve neuropathic pain independently of their antidepressant effect, at an NNT around 3, better than SSRIs (weaker/insufficient data) and comparable to or better than duloxetine (NNT ~5 for diabetic neuropathy). For the depressed patient who also has diabetic neuropathy, post-herpetic neuralgia, or another neuropathic syndrome, a single well-tolerated secondary amine can treat both. Nortriptyline is often preferred over amitriptyline here for tolerability, titrated toward 100–150 mg/day for the pain indication.
Treatment-resistant depression (as a switch or augmentation). Nortriptyline appears in the TRD algorithm as a switch option (it was one of the Step 3 choices in STAR*D, max 200 mg/day there) and as a noradrenergic augmenting agent added to an SSRI. A network meta-analysis of augmentation strategies put nortriptyline augmentation at RR ~2.05 (95% CI 1.02–4.11) vs placebo, a real signal, though from a small sample (n≈23) with a wide confidence interval. The mechanistic logic is sound: layer nortriptyline's noradrenergic action on top of an SSRI's serotonergic one. (See Part 7: this combination raises the tricyclic level and must be done carefully.)
Relapse prevention after ECT: a gold standard. This is the role nortriptyline is best known for. Depression relapse after a successful ECT course is brutal: roughly 80–84% relapse within 6 months on placebo (in Sackeim's landmark 2001 trial, about 24 of 29 placebo patients relapsed). Continuation pharmacotherapy roughly halves that:
- Nortriptyline + lithium: ~35–40% relapse at 6 months (39% in Sackeim 2001, n=28)
- Nortriptyline alone: ~60% relapse at 6 months
- Placebo: ~80% relapse at 6 months
The nortriptyline-plus-lithium combination, two drugs you dose by blood level, became the reference standard for post-ECT continuation. Continuation ECT alone performs about the same as nortriptyline + lithium (no statistical difference at 6 months), and adding continuation ECT to nortriptyline beat nortriptyline alone in late-life psychotic depression (~32% vs ~61% relapse at 1 year). If you are following patients out of an ECT course, this is the regimen to know.
Other supported, off-label roles:
- Migraine and tension-headache prophylaxis (amitriptyline has the longest track record; nortriptyline is better tolerated, a good pick for the depressed headache patient)
- Inflammatory depression: when hs-CRP is elevated (>1 mg/L), nortriptyline and bupropion appear to respond better than SSRIs
- Smoking cessation and ADHD: supported but not preferred; better tools exist for both
Worst Uses / Where Nortriptyline Does Not Belong
- Bipolar depression without a mood stabilizer: tricyclics rank near the top for inducing mania and mixed states
- Borderline personality disorder with impulsivity/suicidality: overdose lethality plus possible disinhibition/aggression
- The acutely suicidal patient with access to a large supply: overdose lethality (dispense small quantities or choose a safer agent)
- Recent MI (within ~6 months) or unstable cardiac / conduction disease
- Untreated narrow-angle glaucoma, significant urinary retention/BPH, uncontrolled seizure disorder: anticholinergic and seizure-threshold concerns
Nortriptyline is a second- or third-line antidepressant by design. Its value is in the specific patient (melancholic, in pain, post-ECT, or SSRI/SNRI-resistant), not in the average depressed patient who hasn't tried anything yet. Reach for it deliberately, for a reason.
Part 2: Before You Start: Workup and Candidacy
Baseline Assessment
| Item | Why |
|---|---|
| ECG | Get one if age >~40, or any cardiac history/risk factor. Establish baseline QTc and screen for conduction delay (wide QRS, bundle branch block, prolonged PR). Tricyclics have type 1A antiarrhythmic effects. |
| Orthostatic vital signs | Baseline, especially in the elderly and fall-prone. Nortriptyline is the least orthostatic TCA, but α1-blockade can still drop pressure. |
| Cardiac history | Recent MI (<6 months), arrhythmia, conduction disease, heart failure: these are the patients to screen hardest or avoid. |
| Suicide-risk assessment | Drives dispensing quantity. Acute risk + large supply = wrong drug or tight quantity limits. |
| Screen for bipolarity | A tricyclic in undiagnosed bipolar depression can flip the patient into mania/mixed state. |
| Anticholinergic-risk review | Narrow-angle glaucoma, BPH/urinary retention, severe constipation, cognitive impairment/dementia. |
| Seizure and medication history | TCAs lower the seizure threshold; map out CYP-interacting drugs (see Part 7). |
Routine baseline LFTs are not required (hepatotoxicity is vanishingly rare, ~4 per 100,000 patient-years); check them only if there's a clinical reason.
Who Is a Poor Candidate?
- Recent MI (<6 months), unstable angina, significant conduction disease or arrhythmia
- Acutely suicidal patients who can't be limited to small supplies
- Untreated narrow-angle glaucoma; significant urinary retention/BPH
- Uncontrolled seizure disorder
- Bipolar depression without a mood stabilizer
- Dementia/significant cognitive impairment (even the least-anticholinergic TCA is a liability here)
Part 3: How to Start and Dose
| Parameter | Value |
|---|---|
| Formulation | Capsules 10 / 25 / 50 / 75 mg; oral solution 10 mg/5 mL |
| Starting dose | 25 mg QHS (10 mg in elderly or drug-sensitive) |
| Titration | Every 5–7 days as tolerated; dose to the serum level, not a fixed mg number |
| Depression target | 75–150 mg/day (guided by level) |
| FDA maximum | 150 mg/day |
| Therapeutic serum window | 50–150 ng/mL (U-shaped — efficacy falls off above 150; come down, don't push up) |
| Neuropathic pain | 100–150 mg/day |
| Renal / hepatic | No fixed adjustment; hepatically metabolized — lower doses and a level in impairment |
| Geriatric | Start 10 mg; the best-tolerated TCA in older adults (low anticholinergic burden, least orthostatic), but still a TCA |
| Cardiac | Baseline ECG if age >40 or cardiac history; conduction effects; overdose cardiotoxic |
| MAOI washout | 14 days in each direction |
Formulation
Nortriptyline hydrochloride comes as capsules (10, 25, 50, 75 mg) and an oral solution (10 mg/5 mL). The liquid is useful for fine titration and for sensitive or elderly patients. All are generic and inexpensive.
Starting Dose and Titration
- Start: 25 mg at bedtime (10 mg in the elderly or the drug-sensitive).
- Titrate every 5–7 days as tolerated. Nothing does more for tolerability than a slow titration; rushing produces anticholinergic and orthostatic side effects that drive patients off the drug.
- Depression target: typically 75–150 mg/day, guided by serum level rather than a fixed milligram number.
- Neuropathic pain: titrate toward 100–150 mg/day, held for at least ~2 weeks to judge the pain response.
- Elderly: start 10 mg, titrate more slowly, and expect a lower final dose.
Nortriptyline can be given once daily at bedtime (its sedation and any anticholinergic effects are then largely slept through), or split if a patient finds a single dose too sedating.
Tricyclics show a dose-response relationship (as do venlafaxine and the MAOIs), unlike SSRIs, where pushing the dose rarely buys more efficacy. If a patient is subtherapeutic by level and not responding, raising the dose is a real intervention, and that is why the blood level matters.
The Serum Level: Nortriptyline's Defining Feature
Nortriptyline is one of only three tricyclics (with imipramine and desipramine) that has a clinically validated, actionable serum level, and it is unique in the class in having a U-shaped ("therapeutic window") efficacy curve: it works best in a band and loses efficacy if the level is too low or too high.
Draw the level 8–12 hours after the last dose, at steady state, meaning at least 5–6 days at a stable dose and longer in slow metabolizers.
The window matters because it inverts the usual intuition. With most drugs, no response means "go higher." With nortriptyline, a patient who stalls or deteriorates at a high dose may be above the window, and the fix is to come down. You cannot know this without a level.
"Fifty to one-fifty, and not a drop more." Below 50, it's not working because there's not enough. Above 150, it's not working because there's too much. The blood level is how you land in between.
Check a level: after reaching a target dose; whenever you add or stop a CYP-interacting drug; in any patient with a cardiac history; and in the TRD or polypharmacy setting, where metabolizer variability is wildest. Clinicians who run TRD clinics describe patients supratherapeutic on 75 mg and subtherapeutic on 200 mg: the same dose lands very differently across metabolizers, and only the level tells you where a given patient sits.
Dose Adjustments and Special Populations
- Geriatric: nortriptyline is the preferred TCA in older adults (among the least anticholinergic, and the least orthostatic of the class), but it is still a tricyclic. Start 10 mg, titrate slowly, and lean on the serum level; expect a lower final dose.
- Hepatic impairment: hepatically metabolized (CYP2D6); use lower doses, titrate cautiously, and check a level.
- Renal impairment: no fixed dose adjustment; use caution and monitor.
- Cardiac disease: baseline ECG in patients over 40 or with cardiac history; TCAs slow conduction (widened QRS/QTc) and overdose is cardiotoxic, so dispense limited quantities in patients at suicide risk.
- Pediatric: safety and efficacy not established for depression; the historical enuresis use has largely been abandoned.
Stopping and Switching
- Discontinuation: taper gradually (over at least 2 weeks) to avoid cholinergic rebound (nausea, malaise, insomnia, vivid dreams).
- MAOI washout: allow 14 days in each direction between nortriptyline and an MAOI.
Part 4: Monitoring
Nortriptyline's monitoring is lighter than lithium's but centers on three things: the level, the heart, and anticholinergic/orthostatic tolerability.
| Timepoint | What to do |
|---|---|
| Baseline | ECG (if >40 or cardiac risk); orthostatic vitals; suicide-risk and dispensing plan |
| Weeks 1–2 | Tolerability check (anticholinergic symptoms, orthostasis, sedation); reassess suicide risk |
| ~Week 2–3 (steady state at target dose) | Serum level (8–12 h post-dose); recheck orthostatic vitals in the elderly |
| After any dose change or new interacting drug | Recheck level once new steady state is reached (~5–6 days) |
| Ongoing (stable) | Periodic anticholinergic/fall-risk review; repeat level if efficacy changes, a new CYP drug is added, or adherence is in question; repeat ECG if the dose is pushed substantially or with a cardiac history |
Routine LFTs and other bloodwork are not needed absent a specific indication. There is no thyroid or renal monitoring burden as there is with lithium (though if you are running the nortriptyline + lithium post-ECT combination, the lithium brings its own full monitoring schedule).
Part 5: Side Effects and How to Manage Them
Nortriptyline is the best-tolerated tricyclic. Most of its side effects are dose- and level-dependent, and many ease over 2–4 weeks if the patient can get through the titration. Manage them early, because with any TCA, side effects, not lack of efficacy, are the usual reason patients quit. A high serum level is often the culprit; check one before assuming true intolerance.
Anticholinergic (Dry Mouth, Constipation, Urinary Retention, Blurred Vision)
Nortriptyline is among the least anticholinergic tricyclics, but "least" is not "none," and these effects still appear, especially in the elderly.
Management
- Dry mouth: sugar-free gum/lozenges, frequent sips of water. Warn about dental decay over time.
- Constipation: fluids, fiber, stool softeners; escalate before it becomes obstruction. Severe, unmanaged constipation risks small-bowel obstruction in the elderly.
- Urinary retention: caution in BPH; watch for hesitancy/retention and the UTIs that follow.
- Blurred vision: usually tolerated and reassurable; can precipitate a crisis in narrow-angle glaucoma, screen for it first.
- Confusion/cognitive fog: more of an issue in older patients; anticholinergic burden is linked to increased dementia risk with chronic exposure. If it appears, lower the dose or reconsider the drug.
- If anticholinergic load is the problem and you must stay in-class, nortriptyline and desipramine are already the lowest-burden options: there's nowhere gentler to switch within the TCAs.
Cardiovascular (Orthostatic Hypotension, Tachycardia, Conduction Effects)
- Orthostatic hypotension / falls: driven by α1-blockade. Nortriptyline is the least orthostatic TCA, which is why it's the tricyclic of choice for fall-prone and elderly patients. Still, start low, titrate slowly, check orthostatic vitals, and counsel slow position changes and adequate hydration.
- Heart rate / conduction: expect a modest resting heart-rate rise (~11%) and reduced heart-rate variability (~14%). Nortriptyline can prolong the QT and, via type 1A sodium-channel blockade, slow conduction. Get the baseline ECG in at-risk patients; repeat it if you push the dose substantially.
- Ischemic heart disease / recent MI: this is the real cardiac danger zone. In active ischemic disease the adverse-cardiac-event rate was markedly higher than with an SSRI (~18% vs ~2%). Avoid within 6 months of an MI and in unstable cardiac disease.
Sedation
Usually mild-to-moderate and often useful in the depressed patient with insomnia. Dose at bedtime. If daytime grogginess persists, lower the dose. Nortriptyline is less sedating than doxepin or amitriptyline.
Weight Gain
Real but generally less than the tertiary amines. Monitor weight; counsel on diet and activity; note that a lower effective dose (guided by the level) also limits it.
Sexual Dysfunction
Counsel patients on a secondary-amine quirk: nortriptyline is less likely to cause anorgasmia than tertiary amines and SSRIs, but more likely to cause erectile dysfunction. Manage with dose/timing adjustment or, if it threatens adherence, targeted augmentation.
Seizure Threshold
Lowered, as with all TCAs. Caution in seizure-prone patients and in traumatic brain injury.
Hepatotoxicity
Extremely rare (~4 per 100,000 patient-years). No routine LFT monitoring needed.
Part 6: Overdose and Toxicity
Overdose toxicity is the most important safety fact about every tricyclic, nortriptyline included, and the precautions below are not optional.
Why TCAs Are Dangerous in Overdose
Tricyclics exert type 1A antiarrhythmic (sodium-channel-blocking) effects on the heart. In overdose this produces widened QRS, conduction blocks, malignant arrhythmias, hypotension, seizures, and cardiovascular collapse. The class carries the highest overdose morbidity and mortality of any antidepressant group (in a National Poison Data System analysis, amitriptyline was among the two most dangerous of 48 antidepressants studied: morbidity index 345/1,000, mortality 3.8/1,000). Nortriptyline shares the class mechanism. A week's extra supply can be a lethal ingestion.
What This Means for Prescribing
- Match dispensing to risk. For any patient with meaningful suicide risk, dispense small quantities (a week or two at a time), enlist family to hold the medication, and reassess risk every visit.
- Prefer a safer agent (SSRI/SNRI) when the patient is acutely suicidal and there's no compelling tricyclic-specific indication.
Overdose means ED evaluation with cardiac monitoring, wide-QRS management (serum alkalinization with sodium bicarbonate), and supportive care. These patients decompensate on the heart, not just the CNS.
Suicidality (Boxed Warning)
Like all antidepressants, nortriptyline carries the suicidality boxed warning: increased risk of suicidal thinking and behavior in children, adolescents, and young adults up to age 24 during early treatment. Monitor closely in the first weeks and after dose changes, especially in the 18–24 group, separate from, and additive to, the overdose-lethality concern above.
Part 7: Drug Interactions
Nortriptyline is metabolized hepatically (principally CYP2D6, with contributions from 2C19 and 1A2). The interactions that matter most are the ones that raise the nortriptyline level, because a level driven above the window costs efficacy and raises toxicity.
Drugs That Raise Nortriptyline Levels (CYP Inhibitors)
- Potent CYP2D6 inhibitors: fluoxetine and paroxetine. The classic offenders. Also bupropion, duloxetine, quinidine.
- Fluvoxamine (CYP1A2/2C19), cimetidine, and many others.
- Mechanism: reduced hepatic clearance leading to a rising tricyclic level and potential toxicity and loss of efficacy (over the top of the window).
- Management: when combining, start low, titrate slowly, and check a level: get a baseline nortriptyline level before adding the inhibitor, then recheck ~2 weeks later. Here nortriptyline's measurable level becomes a safety asset.
Adding low-dose nortriptyline to an SSRI is an established noradrenergic augmentation strategy, but if the SSRI is fluoxetine or paroxetine, that SSRI will also push the nortriptyline level up via CYP2D6 inhibition. Start nortriptyline very low (10–25 mg), go slowly, and let the serum level be your guide.
The "Safe" Antidepressant Partners (Minimal Effect on TCA Levels)
When you need a serotonergic partner without the CYP headache, these do not meaningfully raise tricyclic levels: citalopram, escitalopram, desvenlafaxine, mirtazapine, trazodone, vilazodone, vortioxetine.
Other Interactions to Respect
- MAOIs, contraindicated. The TCA + MAOI combination risks hypertensive crisis and serotonin syndrome. Observe the standard washout (typically ~2 weeks, longer after fluoxetine given its long half-life).
- Serotonin syndrome: possible with other serotonergic agents (lower risk than the more serotonergic clomipramine, but present); watch for agitation, tremor, hyperthermia, rigidity.
- Sympathomimetics (e.g., pseudoephedrine): risk of pressor effects.
- Additive anticholinergics / CNS depressants / alcohol: additive burden, review the whole med list.
- QT-prolonging drugs: additive QT risk; more caution and an ECG.
Part 8: Special Populations
Pregnancy
Nortriptyline is among the better-studied tricyclics in pregnancy and does not carry a specific major-malformation signal on the scale of, say, valproate. As always, weigh it against the substantial risks of untreated depression in pregnancy. Watch for neonatal adaptation/withdrawal (jitteriness, feeding issues, respiratory symptoms) with third-trimester exposure, and coordinate with obstetrics. Nortriptyline's measurable level is an advantage here: because clearance shifts across pregnancy, you can track the level and adjust the dose to keep the mother in the window rather than dosing blind.
Lactation
Nortriptyline is generally considered relatively compatible with breastfeeding among antidepressants; infant serum levels are typically low or undetectable. Monitor the infant for sedation and feeding, and coordinate with pediatrics. (When part of a post-ECT nortriptyline + lithium regimen, the lithium, not the nortriptyline, is the component that complicates breastfeeding decisions.)
Elderly
Tricyclics are broadly discouraged in older adults (anticholinergic burden, falls, confusion, dementia-risk association), yet nortriptyline is the specific TCA you choose when there is a clear case for a tricyclic in this group, because it is among the least anticholinergic and the least orthostatic. If you use it:
- Start 10 mg, titrate slowly, target a lower final dose.
- Baseline ECG and orthostatic vitals; recheck orthostatics as you titrate.
- Watch cognition, continence, bowels, and falls.
- Reserve it for clear indications (melancholic depression, neuropathic pain) rather than routine geriatric depression, where an SSRI is usually first.
Renal and Hepatic Impairment
- Hepatic: nortriptyline is cleared by the liver; use caution and reduce dose in significant hepatic impairment; the serum level is especially valuable for guiding dose here.
- Renal: no dramatic clearance-driven dose adjustment is mandated, but frail/renally impaired patients tolerate side effects less well, so start low and lean on the level.
Children and Adolescents
Not a preferred agent (limited efficacy data for pediatric depression across TCAs; overdose lethality; the boxed suicidality warning is most pointed in the young). Not first-line for ADHD or smoking cessation either. Use, if at all, only with specialist involvement and careful risk management.
Part 9: Discontinuation
Tricyclics are generally easier to stop than the SNRIs (venlafaxine, duloxetine) or the short-half-life SSRIs (paroxetine, fluvoxamine), but "easier" is not "just stop."
- Taper gradually. Abrupt cessation can produce a cholinergic-rebound discontinuation syndrome (nausea, GI upset, malaise, sleep disturbance, sometimes a flu-like picture) and, more seriously, risks relapse of the underlying depression.
- Abrupt withdrawal has also been associated with withdrawal-emergent dyskinesias in the weeks after stopping.
- A slow taper over weeks, with a plan to resume promptly if depressive symptoms re-emerge, is the safe approach. As with any effective antidepressant, it is far easier to prevent a relapse than to re-treat a full episode.
Part 10: Nortriptyline vs the Alternatives
vs Amitriptyline (its parent tertiary amine). Same efficacy neighborhood, far better tolerability. Amitriptyline is the most anticholinergic and among the most orthostatic and most overdose-dangerous TCAs; nortriptyline is among the least anticholinergic and the least orthostatic. Amitriptyline has the longer pain/headache track record, but for most patients who need a tricyclic, nortriptyline is the better-tolerated way to get there.
vs Desipramine. The other secondary amine, similarly low in anticholinergic burden and also level-guided (target >125 ng/mL). Some clinicians prefer desipramine for its dosing flexibility: it lacks nortriptyline's upper efficacy ceiling, so you can push it without falling off a window. Nortriptyline's countervailing advantage is the best-validated, most-studied therapeutic window in the class. Reasonable clinicians choose between them by feel and by which level target they'd rather manage.
vs SSRIs. SSRIs win on overdose safety, cardiac safety, anticholinergic burden, and first-line simplicity, which is why they are first-line. Nortriptyline wins for melancholic depression, neuropathic-pain comorbidity, IBS-comorbid depression, and inflammatory depression (elevated CRP), and offers a measurable level. Choose the SSRI for the average patient; choose nortriptyline for the specific one.
vs SNRIs (duloxetine, venlafaxine). For neuropathic pain, tricyclics are at least as effective (NNT ~3 vs duloxetine's ~5) and cheaper, but SNRIs are far safer in overdose and better tolerated overall. For depression-plus-pain in a patient at low overdose risk, nortriptyline is a strong single-drug answer; the SNRIs are the safer default.
vs MAOIs. MAOIs are the escalation beyond tricyclics for atypical and truly refractory depression (a meaningful fraction of TCA non-responders respond to tranylcypromine). Different tier, different risk profile, and contraindicated with a TCA.
Why use nortriptyline at all, given SSRIs exist? Because for the melancholic patient, the patient in neuropathic pain, the post-ECT patient, and the SSRI/SNRI-resistant patient, it does something those drugs do less well, and it does it as the most tolerable, most measurable member of an otherwise blunt class.
Mechanism
Nortriptyline is the secondary-amine active metabolite of amitriptyline. Its primary antidepressant action is inhibition of norepinephrine reuptake (via the norepinephrine transporter), with only weak serotonin-reuptake activity. That is the reverse of the tertiary tricyclics' emphasis, and the reason it's more "noradrenergic" and less serotonergic than amitriptyline. As a secondary amine, it has shed much of the off-target receptor binding that makes tertiary TCAs miserable: it is comparatively weak at muscarinic (anticholinergic), α1-adrenergic (orthostatic), and H1-histaminergic (sedating) receptors, hence its cleaner profile.
The same molecule's liability is cardiac: like all tricyclics it exerts type 1A antiarrhythmic (fast sodium-channel-blocking) effects on cardiac conduction, which are benign at therapeutic levels in a healthy heart but are the mechanism of its lethality in overdose and its caution in cardiac disease. TCAs also downregulate β-adrenergic receptors over weeks (a classic correlate of the delayed antidepressant response) and have NMDA-modulating and descending-pain-pathway (serotonin/norepinephrine) effects that likely underlie the analgesic benefit running independent of mood.
The Bedside Cheat Sheet
Who it's for
- Melancholic depression (beats SSRIs), depression + neuropathic pain (NNT ~3), TRD (switch/augment), post-ECT maintenance (nortriptyline + lithium = gold standard).
- Best-tolerated TCA; among the least anticholinergic; least orthostatic; the TCA for fall-prone/elderly when a TCA is indicated.
Starting
- 25 mg QHS (10 mg elderly); titrate every 5–7 days.
- Depression target 75–150 mg/day; neuropathic pain 100–150 mg/day.
- Dose at bedtime (sleep through sedation/anticholinergic effects).
The level
- Window 50–150 ng/mL. U-shaped: too low or too high both fail.
- Draw 8–12 h post-dose, at steady state (≥5–6 days at a stable dose).
- Recheck after any dose change or new CYP-interacting drug; check in cardiac/TRD/polypharmacy patients.
- Dose-response is real for TCAs: a subtherapeutic level is worth correcting.
Monitoring
- Baseline ECG if >40 or cardiac risk; orthostatic vitals (elderly).
- Tolerability check weeks 1–2; level at steady state; repeat level/ECG as above.
Side effects
- Anticholinergic (least of the TCAs, but real): dry mouth, constipation, retention, blurred vision, fluids/fiber/lozenges, watch glaucoma/BPH.
- Orthostasis/falls: least of the TCAs; start low, check orthostatics.
- Cardiac: ~+11% HR, ↓HRV, QT/conduction; avoid <6 mo post-MI and in unstable cardiac disease.
- Sedation (dose QHS), weight gain (less than tertiaries), sexual dysfunction (less anorgasmia, more ED).
Don't forget
- Lethal in overdose (type 1A cardiac toxicity): dispense small quantities to at-risk patients; overdose is an ED/cardiac emergency (treat QRS widening with bicarbonate).
- Boxed warning: suicidality in patients ≤24, monitor closely early.
- Fluoxetine/paroxetine (and bupropion, duloxetine) raise the level via CYP2D6, start low, check a level. "Safe" partners: citalopram, escitalopram, desvenlafaxine, mirtazapine, trazodone, vilazodone, vortioxetine.
- MAOIs contraindicated (washout ~2 weeks). No tricyclic in bipolar depression without a mood stabilizer.
- Taper, don't stop abruptly (cholinergic rebound + relapse risk).
Nortriptyline asks more of the prescriber than an SSRI does: an ECG in the right patients, a blood level, attention to overdose risk, and a slow titration. In return you get a precise, measurable, well-tolerated antidepressant for the patients the first-line drugs leave behind: the melancholic patient, the patient in pain, the one just out of ECT, and the one who has failed the easy options. It is not a drug for everyone and should not be. Prescribed deliberately to the right patient, with a level in hand and a plan for the heart and the pill count, it remains one of the most useful second-line tools in psychiatry and the one tricyclic every prescriber should still know how to use.